Ikena Oncology, (id:6744 IKNA)
1.71 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:33:06 PM)
Exchange closed, opens in 1 day 10 hours
-0.58 USD (-0.58%)
0.00 USD (0.00%)
1.18 USD (1.18%)
27.61 USD (27.61%)
6.21 USD (6.21%)
-92.37 USD (-92.37%)
About Ikena Oncology,
Market Capitalization 81.56M
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Headquarters (address) |
645 Summer Street Boston 02210 MA United States |
| Phone | 857 273 8343 |
| Website | https://ikenaoncology.com |
| Employees | 43 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | IKNA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.22 - 2.32 |
| Market Capitalization | 81.56M |
| P/E trailing | -1.05 |
| P/E forward | -1.99 |
| Price/Sale | 123.76 |
| Price/Book | 0.607 |
| Beta | 0.485 |
| EPS | -1.23 |
| EPS United States (ID:6, base:3403) | 24.22 |